Real-World Evidence (RWE) & Data Standards
Global RWD landscapes in US, EU and UK and implications for RWE
Understanding Global Real-World Data Landscapes: Implications for Real-World Evidence As the pharmaceutical and medtech industries increasingly rely on real-world data (RWD) to inform and support regulatory decision-making, it becomes essential to comprehend the broad array of data sources available and the regulatory frameworks governing their use. This tutorial serves as a comprehensive guide for professionals involved in regulatory affairs, biostatistics, health economics and outcomes research (HEOR), and data standards. It will explore real-world data sources such as claims, electronic health records (EHR), patient registries, and digital health data across the US, EU, and UK landscapes. Step 1: Defining Real-World Data…
Handling missingness and coding variability across RWD sources
Handling Missingness and Coding Variability Across RWD Sources Handling Missingness and Coding Variability Across RWD Sources Real-World Data (RWD) has increasingly become pivotal for generating insights into patient outcomes and treatment efficacy in the pharmaceutical and medtech industries. However, significant challenges arise, particularly regarding missingness and coding variability across diverse data sources such as claims data, Electronic Health Records (EHRs), patient registries, and digital health data. This comprehensive guide provides a step-by-step tutorial for navigating these complexities, ensuring regulatory compliance, and optimizing data utilization for real-world evidence (RWE). Understanding Real-World Data Sources Real-World Data encompasses various non-experimental data sources that…
Case studies of RWD source selection in successful RWE submissions
Case studies of RWD source selection in successful RWE submissions Case Studies of RWD Source Selection in Successful RWE Submissions In the realm of pharmaceutical and medical device development, the integration of Real-World Data (RWD) into evidence generation has transformed the landscape of regulatory submissions. This article aims to provide a comprehensive guide on the selection of Real-World Data Sources, focusing on case studies that demonstrate successful Real-World Evidence (RWE) submissions. Understanding the nuances of RWD, including claims data, Electronic Health Records (EHR), patient registries, and digital health data is crucial for regulatory, biostatistics, Health Economics and Outcomes Research (HEOR),…
Data partner selection criteria for high value RWD collaborations
Data Partner Selection Criteria for High Value RWD Collaborations In the evolving landscape of healthcare and pharmaceutical innovation, the need for robust real-world data (RWD) has never been more critical. This tutorial serves as a comprehensive guide for regulatory, biostatistics, health economics and outcomes research (HEOR), and data standards professionals tasked with selecting the right data partners for high-value RWD collaborations. The focus will be on key criteria for evaluating partnerships with a myriad of real-world data sources, including claims, electronic health records (EHR), patient registries, and digital health data. This is essential not just to meet regulatory expectations but…
Linking claims, EHR and registry data for richer RWE insights
Linking Claims, EHR and Registry Data for Richer RWE Insights In the evolving landscape of healthcare, the utilization of real-world data sources is becoming increasingly crucial for driving evidence-based decision making. Regulatory, biostatistics, health economics and outcomes research (HEOR), and data standards professionals in the pharmaceutical and medtech industries are particularly focused on harnessing the robust insights available from claims data, electronic health records (EHR), patient registries, and digital health data. This article presents a comprehensive step-by-step guide for linking these diverse data sources in compliance with US FDA regulations, as well as comparing practices in the UK and EU…
KPIs to track RWD asset utilisation and ROI for RWE programs
KPI Tracking for Real-World Data Asset Utilization and ROI in RWE Programs In the evolving landscape of healthcare, the importance of real-world data (RWD) and real-world evidence (RWE) is undeniable. Regulatory, biostatistics, and data standards professionals in pharma and medtech sectors must equip themselves with the knowledge to monitor and evaluate the effectiveness of their RWD assets. This comprehensive guide outlines the critical Key Performance Indicators (KPIs) necessary for tracking the utilization of RWD assets and determining the return on investment (ROI) for RWE programs. We will focus on key data sources such as claims data, electronic health records (EHR),…
Architectures for integrating digital health data into RWE pipelines
Architectures for Integrating Digital Health Data into RWE Pipelines As healthcare systems evolve, the integration of digital health data into Real-World Evidence (RWE) pipelines has become pivotal for regulatory, biostatistics, health economics and outcomes research (HEOR), and data standards professionals. This comprehensive guide provides a step-by-step approach to understanding the frameworks and regulatory implications of using real-world data (RWD) sources such as claims, Electronic Health Records (EHR), patient registries, and digital health information. Understanding Real-World Evidence (RWE) and Real-World Data (RWD) Real-World Evidence (RWE) represents the clinical evidence derived from the analysis of Real-World Data (RWD) relating to patient health…
Assessing fitness for purpose of RWD sources for specific RWE questions
Assessing fitness for purpose of RWD sources for specific RWE questions Assessing Fitness for Purpose of RWD Sources for Specific RWE Questions Real-world evidence (RWE) plays a critical role in shaping regulatory decisions, supporting health economics outcomes research (HEOR), and informing clinical practices. The assessment of real-world data (RWD) sources—such as claims data, electronic health records (EHR), patient registries, and digital health data—is pivotal in ensuring they are fit for the specific questions posed by RWE research. This article provides a comprehensive guide for regulatory, biostatistics, HEOR, RWE, and data standards professionals in the pharma and medtech sectors, focusing on…
Building internal RWD lakes and federated data networks for RWE
Introduction to Real-World Data (RWD) and Real-World Evidence (RWE) The evolving landscape of healthcare, characterized by an increasing demand for effective, cost-efficient treatments, has positioned Real-World Data (RWD) and Real-World Evidence (RWE) at the forefront of medical research and regulatory review. RWD refers to data collected outside the controlled environment of traditional clinical trials, encompassing various forms such as electronic health records (EHR), claims data, patient registries, and wearable device data. RWE, meanwhile, reflects the clinical and economic outcomes derived from analyzing this data, providing valuable insights into a product’s performance in a real-world setting. In the context of regulatory…
Propensity scores, IPTW and matching methods for confounding control
Propensity Scores, IPTW, and Matching Methods for Confounding Control In the field of Real-World Evidence (RWE) submissions to the FDA, the correct application of statistical methods is critical for generating reliable results that support regulatory decisions. This article provides a detailed step-by-step guide on using propensity scores, inverse probability of treatment weighting (IPTW), and matching methods as effective strategies for confounding control in your RWE study design methodology. Understanding the Basics of Confounding in RWE Studies Confounding occurs when an external variable influences both the treatment and outcome, leading to biased estimates of treatment effects. For RWE studies, which often…